CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 75 of 111 entries

View as:

Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND

Phase: N/A Priority: Normal

NCT ID: NCT00161720 Org: User:

Start: 06/01/05 End: 12/01/05 Due: 12/01/06

BAX 326 Pediatric Study

Phase: N/A Priority: Normal

NCT ID: NCT01488994 Org: User:

Start: 12/20/11 End: 05/14/13 Due: 05/14/14

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Phase: N/A Priority: Normal

NCT ID: NCT00851721 Org: User:

Start: 03/31/09 End: 10/17/12 Due: 10/17/13

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

Phase: N/A Priority: Normal

NCT ID: NCT00157157 Org: User:

Start: 04/01/04 End: 09/11/09 Due: 09/11/10

Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A

Phase: N/A Priority: Normal

NCT ID: NCT02634723 Org: User:

Start: 12/23/15 End: 06/30/16 Due: 06/30/17

Ceprotin Treatment Registry

Phase: N/A Priority: Normal

NCT ID: NCT01127529 Org: User:

Start: 06/23/10 End: 06/22/15 Due: 06/22/16

Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia

Phase: N/A Priority: Normal

NCT ID: NCT03185897 Org: User:

Start: 06/14/17 End: 03/17/21 Due: 03/17/22

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Phase: N/A Priority: Normal

NCT ID: NCT01174446 Org: User:

Start: 07/29/10 End: 05/03/12 Due: 05/03/13

Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer

Phase: N/A Priority: Normal

NCT ID: NCT02540356 Org: User:

Start: 11/02/15 End: 05/26/16 Due: 05/26/17

BAX 326 (rFIX) Continuation Study

Phase: N/A Priority: Normal

NCT ID: NCT01286779 Org: User:

Start: 04/12/11 End: 06/29/17 Due: 06/29/18

Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea

Phase: N/A Priority: Normal

NCT ID: NCT02922231 Org: User:

Start: 01/06/17 End: 04/04/19 Due: 04/04/20

Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal

Phase: N/A Priority: Normal

NCT ID: NCT01159210 Org: User:

Start: 07/09/10 End: 04/07/12 Due: 04/07/13

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Phase: N/A Priority: Normal

NCT ID: NCT02610127 Org: User:

Start: 12/30/15 End: 06/07/19 Due: 06/07/20

Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)

Phase: N/A Priority: Normal

NCT ID: NCT03716700 Org: User:

Start: 09/24/18 End: 07/23/20 Due: 07/23/21

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Phase: N/A Priority: Normal

NCT ID: NCT02549170 Org: User:

Start: 12/15/15 End: 02/23/22 Due: 02/23/23

RIXUBIS Drug Use-Result Survey (Japan)

Phase: N/A Priority: Normal

NCT ID: NCT02937831 Org: User:

Start: 11/16/16 End: 05/11/22 Due: 05/11/23

Early Prophylaxis Immunologic Challenge (EPIC) Study

Phase: N/A Priority: Normal

NCT ID: NCT01376700 Org: User:

Start: 08/26/11 End: 11/16/12 Due: 11/16/13

First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients

Phase: N/A Priority: Normal

NCT ID: NCT01191372 Org: User:

Start: 09/15/10 End: 12/28/11 Due: 12/28/12

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Phase: N/A Priority: Normal

NCT ID: NCT00546871 Org: User:

Start: 10/03/07 End: 09/01/09 Due: 09/01/10

ADVATE Post Authorization Safety Surveillance

Phase: N/A Priority: Normal

NCT ID: NCT00214734 Org: User:

Start: 10/14/04 End: 03/02/07 Due: 03/02/08

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Phase: N/A Priority: Normal

NCT ID: NCT00816660 Org: User:

Start: 12/01/08 End: 08/31/10 Due: 08/31/11

Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously

Phase: N/A Priority: Normal

NCT ID: NCT00333515 Org: User:

Start: 01/01/07 End: 08/01/08 Due: 08/01/09

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Phase: N/A Priority: Normal

NCT ID: NCT00157053 Org: User:

Start: 11/22/01 End: 08/03/04 Due: 08/03/05

Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients

Phase: N/A Priority: Normal

NCT ID: NCT00162019 Org: User:

Start: 03/31/03 End: 08/24/04 Due: 08/24/05

Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Phase: N/A Priority: Normal

NCT ID: NCT01968655 Org: User:

Start: - End: - Due: -

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND	NCT00161720	Baxalta now part of Shire	user2@example.com	None	2005-06-01	2005-12-01	2006-12-01	-	-	2025-07-14
BAX 326 Pediatric Study	NCT01488994	Baxalta now part of Shire	user2@example.com	None	2011-12-20	2013-05-14	2014-05-14	-	-	2025-07-14
Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor	NCT00851721	Baxalta now part of Shire	user2@example.com	None	2009-03-31	2012-10-17	2013-10-17	-	-	2025-07-14
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients	NCT00157157	Baxalta now part of Shire	user2@example.com	None	2004-04-01	2009-09-11	2010-09-11	-	-	2025-07-14
Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A	NCT02634723	Baxalta now part of Shire	user2@example.com	None	2015-12-23	2016-06-30	2017-06-30	-	-	2025-07-14
Ceprotin Treatment Registry	NCT01127529	Baxalta now part of Shire	user2@example.com	None	2010-06-23	2015-06-22	2016-06-22	-	-	2025-07-14
Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia	NCT03185897	Baxalta now part of Shire	user2@example.com	None	2017-06-14	2021-03-17	2022-03-17	-	-	2025-07-14
Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients	NCT01174446	Baxalta now part of Shire	user2@example.com	None	2010-07-29	2012-05-03	2013-05-03	-	-	2025-07-14
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer	NCT02540356	Baxalta now part of Shire	user2@example.com	None	2015-11-02	2016-05-26	2017-05-26	-	-	2025-07-14
BAX 326 (rFIX) Continuation Study	NCT01286779	Baxalta now part of Shire	user2@example.com	None	2011-04-12	2017-06-29	2018-06-29	-	-	2025-07-14
Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea	NCT02922231	Baxalta now part of Shire	user2@example.com	None	2017-01-06	2019-04-04	2020-04-04	-	-	2025-07-14
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal	NCT01159210	Baxalta now part of Shire	user2@example.com	None	2010-07-09	2012-04-07	2013-04-07	-	-	2025-07-14
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A	NCT02610127	Baxalta now part of Shire	user2@example.com	None	2015-12-30	2019-06-07	2020-06-07	-	-	2025-07-14
Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)	NCT03716700	Baxalta now part of Shire	user2@example.com	None	2018-09-24	2020-07-23	2021-07-23	-	-	2025-07-14
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)	NCT02549170	Baxalta now part of Shire	user2@example.com	None	2015-12-15	2022-02-23	2023-02-23	-	-	2025-07-14
RIXUBIS Drug Use-Result Survey (Japan)	NCT02937831	Baxalta now part of Shire	user2@example.com	None	2016-11-16	2022-05-11	2023-05-11	-	-	2025-07-14
Early Prophylaxis Immunologic Challenge (EPIC) Study	NCT01376700	Baxalta now part of Shire	user2@example.com	None	2011-08-26	2012-11-16	2013-11-16	-	-	2025-07-14
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients	NCT01191372	Baxalta now part of Shire	user2@example.com	None	2010-09-15	2011-12-28	2012-12-28	-	-	2025-07-14
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects	NCT00546871	Baxalta now part of Shire	user2@example.com	None	2007-10-03	2009-09-01	2010-09-01	-	-	2025-07-14
ADVATE Post Authorization Safety Surveillance	NCT00214734	Baxalta now part of Shire	user2@example.com	None	2004-10-14	2007-03-02	2008-03-02	-	-	2025-07-14
Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease	NCT00816660	Baxalta now part of Shire	user2@example.com	None	2008-12-01	2010-08-31	2011-08-31	-	-	2025-07-14
Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously	NCT00333515	Baxalta now part of Shire	user2@example.com	None	2007-01-01	2008-08-01	2009-08-01	-	-	2025-07-14
Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901	NCT00157053	Baxalta now part of Shire	user2@example.com	None	2001-11-22	2004-08-03	2005-08-03	-	-	2025-07-14
Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients	NCT00162019	Baxalta now part of Shire	user2@example.com	None	2003-03-31	2004-08-24	2005-08-24	-	-	2025-07-14
Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies	NCT01968655	Baxalta now part of Shire	user2@example.com	None	-	-	-	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance